A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Trial Profile

A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech; BioTech Tools
  • Most Recent Events

    • 30 May 2017 According to an ASIT biotech media release, data from thsis study will be presented at at the European Academy of Allergy and Clinical Immunology (EAACI) 2017.
    • 28 Feb 2017 According to an ASIT biotech media release, company is planning to discuss the study results with regulatory agencies in Germany and the US regarding gp-ASIT+™ clinical development.
    • 28 Feb 2017 According to an ASIT biotech media release, following additional analyses, full results will be presented at upcoming scientific meetings and will be reported in a research article which will be published in scientific journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top